Zilucoplan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 88 publications

Fibrosing Skin Disorder Associated With Zilucoplan.

Fibrosing Skin Disorder Associated With Zilucoplan.

Journal: JAMA dermatology

Published: August 19, 2026

A rare case of morphea following zilucoplan treatment for generalized myasthenia gravis.

A rare case of morphea following zilucoplan treatment for generalized myasthenia gravis.

Journal: JAAD case reports

Published: August 16, 2026

Clinical efficacy and cost per improved outcome of treatments for generalized myasthenia gravis: evidence from a network meta-analysis and cost-per-responder analysis.

Clinical efficacy and cost per improved outcome of treatments for generalized myasthenia gravis: evidence from a network meta-analysis and cost-per-responder analysis.

Journal: Current medical research and opinion

Published: July 24, 2026

Inebilizumab (Uplizna) for myasthenia gravis.

Inebilizumab (Uplizna) for myasthenia gravis.

Journal: The Medical letter on drugs and therapeutics

Published: June 25, 2026

Case Report: Zilucoplan in refractory myasthenic crisis and its prodromal stages: a novel therapeutic perspective.

Case Report: Zilucoplan in refractory myasthenic crisis and its prodromal stages: a novel therapeutic perspective.

Journal: Frontiers in neuroscience

Published: May 20, 2026

Nipocalimab (Imaavy) for myasthenia gravis.

Nipocalimab (Imaavy) for myasthenia gravis.

Journal: The Medical letter on drugs and therapeutics

Published: May 15, 2026

Site-targeted proximal complement C3 inhibition, but not C5 blockade, attenuates neurodegeneration in a mouse model of amyotrophic lateral sclerosis: Implications for failed clinical trials.

Site-targeted proximal complement C3 inhibition, but not C5 blockade, attenuates neurodegeneration in a mouse model of amyotrophic lateral sclerosis: Implications for failed clinical trials.

Journal: Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics

Published: April 02, 2026

Real-world effectiveness and safety of zilucoplan in patients with anti-AChR myasthenia gravis: A retrospective cohort study in France.

Real-world effectiveness and safety of zilucoplan in patients with anti-AChR myasthenia gravis: A retrospective cohort study in France.

Journal: Journal of neuromuscular diseases

Published: March 29, 2026

Zilucoplan as a rescue therapy in myasthenic crisis: a case description and summary of early report experiences.

Zilucoplan as a rescue therapy in myasthenic crisis: a case description and summary of early report experiences.

Journal: Acta neurologica Belgica

Published: March 01, 2026

Combined inhibition of complement C5 and neonatal Fc receptor in refractory generalized myasthenia gravis: A report of two cases.

Combined inhibition of complement C5 and neonatal Fc receptor in refractory generalized myasthenia gravis: A report of two cases.

Journal: Journal of neuroimmunology

Published: February 07, 2026

Rapid Symptomatic Improvement and Long-Term Minimal Symptom Expression in a Myasthenia Gravis Patient Treated With Zilucoplan Without Maintenance Cholinesterase Inhibitors, Corticosteroids, or Immunosuppressants: A Case Report.

Rapid Symptomatic Improvement and Long-Term Minimal Symptom Expression in a Myasthenia Gravis Patient Treated With Zilucoplan Without Maintenance Cholinesterase Inhibitors, Corticosteroids, or Immunosuppressants: A Case Report.

Journal: Cureus

Published: January 28, 2026

Authors' reply to comment letter on ZILU25 study.

Authors' reply to comment letter on ZILU25 study.

Journal: Journal of the neurological sciences

Published: January 13, 2026

Showing 1-12 of 88

Last Updated: 09/26/2026